We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.
- Authors
Kawabata-Iwakawa, Reika; Iwasa, Norihiro; Satoh, Kenichi; Colinge, Jacques; Shimada, Muneaki; Takeuchi, Satoshi; Fujiwara, Hiroyuki; Eguchi, Hidetaka; Oishi, Tetsuro; Sugiyama, Toru; Suzuki, Mitsuaki; Hasegawa, Kosei; Fujiwara, Keiichi; Nishiyama, Masahiko
- Abstract
Background: Platinum/taxane (TC) chemotherapy with debulking surgery stays the mainstay of the treatment in ovarian cancer patients with peritoneal metastasis, and recently its novel modality, intraperitoneal carboplatin with dose-dense paclitaxel (ddTCip), was shown to have greater therapeutic impact. Nevertheless, the response varies among patients and consequent recurrence, or relapse often occurs. Discovery of therapeutic response predictor to ddTCip and/or TC therapy is eagerly awaited to improve the treatment outcome. Methods: Using datasets in 76 participants in our ddTCip study and published databases on patients received TC therapy, we first validated a total of 75 previously suggested markers, sought out more active biomarkers through the association analyses of genome-wide transcriptome and genotyping data with progression-free survival (PFS) and adverse events, and then developed multiplex statistical prediction models for PFS and toxicity by mainly using multiple regression analysis and the classification and regression tree (CART) algorithm. Results: The association analyses revealed that SPINK1 could be a possible biomarker of ddTCip efficacy, while ABCB1 rs1045642 and ERCC1 rs11615 would be a predictor of hematologic toxicity and peripheral neuropathy, respectively. Multiple regression analyses and CART algorithm finally provided a potent efficacy prediction model using 5 gene expression data and robust multiplex toxicity prediction models-CART models using a total of 4 genotype combinations and multiple regression models using 15 polymorphisms on 12 genes. Conclusion: Biomarkers and multiplex models composed here could work well in the response prediction of ddTCip and/or TC therapy, which might contribute to realize optimal selection of the key therapy.
- Subjects
MULTIPLE regression analysis; REGRESSION analysis; CART algorithms; TUMOR markers; CANCER chemotherapy
- Publication
International Journal of Clinical Oncology, 2024, Vol 29, Issue 9, p1334
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-024-02552-w